BIOMAT Database Logo BIOMAT Database Logo

Luteinising hormone releasing hormone analogue for prostatic cancer. 1985

M C Taylor

UI MeSH Term Description Entries
D007987 Gonadotropin-Releasing Hormone A decapeptide that stimulates the synthesis and secretion of both pituitary gonadotropins, LUTEINIZING HORMONE and FOLLICLE STIMULATING HORMONE. GnRH is produced by neurons in the septum PREOPTIC AREA of the HYPOTHALAMUS and released into the pituitary portal blood, leading to stimulation of GONADOTROPHS in the ANTERIOR PITUITARY GLAND. FSH-Releasing Hormone,GnRH,Gonadoliberin,Gonadorelin,LH-FSH Releasing Hormone,LHRH,Luliberin,Luteinizing Hormone-Releasing Hormone,Cystorelin,Dirigestran,Factrel,Gn-RH,Gonadorelin Acetate,Gonadorelin Hydrochloride,Kryptocur,LFRH,LH-RH,LH-Releasing Hormone,LHFSH Releasing Hormone,LHFSHRH,FSH Releasing Hormone,Gonadotropin Releasing Hormone,LH FSH Releasing Hormone,LH Releasing Hormone,Luteinizing Hormone Releasing Hormone,Releasing Hormone, LHFSH
D008297 Male Males
D011471 Prostatic Neoplasms Tumors or cancer of the PROSTATE. Cancer of Prostate,Prostate Cancer,Cancer of the Prostate,Neoplasms, Prostate,Neoplasms, Prostatic,Prostate Neoplasms,Prostatic Cancer,Cancer, Prostate,Cancer, Prostatic,Cancers, Prostate,Cancers, Prostatic,Neoplasm, Prostate,Neoplasm, Prostatic,Prostate Cancers,Prostate Neoplasm,Prostatic Cancers,Prostatic Neoplasm
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

M C Taylor
Biodegradable polymer luteinising hormone releasing hormone analogue for prostatic cancer: use of a new peptide delivery system.
December 1984, British medical journal (Clinical research ed.),
M C Taylor
Combined treatment with ketoconazole and luteinising hormone releasing hormone analogue: a novel approach to resistant progressive prostatic cancer.
December 1983, British medical journal (Clinical research ed.),
M C Taylor
Failure of long term luteinising hormone releasing hormone treatment for prostatic cancer to suppress serum luteinising hormone and testosterone.
September 1984, British medical journal (Clinical research ed.),
M C Taylor
Failure of long term luteinising hormone releasing hormone treatment for prostatic cancer to suppress serum luteinising hormone and testosterone.
August 1984, British medical journal (Clinical research ed.),
M C Taylor
Pharmacology of the luteinising hormone-releasing hormone (LHRH) analogue, Zoladex.
January 1989, Hormone research,
M C Taylor
A recombinant luteinising-hormone-releasing-hormone immunogen bioeffective in causing prostatic atrophy.
September 2004, Vaccine,
M C Taylor
Treatment with a luteinising-hormone-releasing-hormone analogue (buserelin) in premenopausal patients with metastatic breast cancer.
May 1982, Lancet (London, England),
M C Taylor
Treatment with gonadotrophin releasing hormone analogue in advanced prostatic cancer.
April 1983, British medical journal (Clinical research ed.),
M C Taylor
Luteinising hormone releasing hormone (LHRH).
February 1978, Drug and therapeutics bulletin,
M C Taylor
Does needle size matter? Patient experience of luteinising hormone-releasing hormone analogue injection.
January 2005, Prostate cancer and prostatic diseases,
Copied contents to your clipboard!